Ghent, Belgium

Jimmy Borloo

USPTO Granted Patents = 2 

 

 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2018-2021

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Jimmy Borloo

Introduction

Jimmy Borloo is a notable inventor based in Ghent, Belgium. He has made significant contributions to the field of vaccine development, particularly focusing on nucleotide sequences and recombinant DNA technologies. With a total of 2 patents, his work is paving the way for advancements in immunology.

Latest Patents

Borloo's latest patents include groundbreaking inventions related to vaccines. The first patent involves nucleotide sequences encoding antigens, as well as recombinant DNA molecules that contain these sequences. This invention also encompasses host cells that express these nucleotide sequences. Furthermore, it relates to proteins and methods for their production, ultimately leading to vaccines that induce protective immunity against infections by parasitic nematodes. His second patent, the Cooperia vaccine, shares similar characteristics, focusing on the same nucleotide sequences and their applications in vaccine development.

Career Highlights

Jimmy Borloo is affiliated with Universiteit Gent, where he conducts his research and development activities. His work has garnered attention for its innovative approach to tackling parasitic infections through vaccine technology.

Collaborations

Borloo collaborates with esteemed colleagues such as Peter Geldhof and Edwin Claerebout, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

In summary, Jimmy Borloo's contributions to vaccine development through his patents and collaborations highlight his role as a key innovator in the field. His work continues to inspire advancements in immunology and public health.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…